Treatment for COVID-19 across the possible use of monoclonal antibodies and antiviral agents: clinical, epidemiological, virological, and immunological aspects

  • 5,925

    Total downloads

  • 18k

    Total views and downloads

About this Research Topic

Submission closed

Background

Since the beginning of 2021, there have been different therapies authorized against SARS-CoV-2 for early mild-to-moderate COVID-19 and for use in hospitalized patients. Monoclonal antibodies, single or in combination, and antiviral agents have been widely used worldwide and across the variant era.

The efficacy of these drugs as early treatment for mild-to-moderate COVID-19 has been demonstrated in phase 3 trials in terms of reduction of risk of hospitalization/death in high-risk patients. Nevertheless, in vitro, data questioned the efficacy of monoclonal antibodies against the Omicron sublineages based on the reduced neutralization activity. Moreover, the Omicron era has been characterized by a high rate of vaccinated people and a lower probability of hospitalization, which are very different from the phase 3 trials mentioned above: in this scenario, it would be very difficult to assess the impact of the treatment on the “classical” endpoint of clinical failure, and it will be reasonable to investigate other outcome and aspects related with early therapies.

In addition, both antiviral and monoclonal antibodies have been used in severe COVID-19 in hospitalized patients with specific characteristics. Currently, new strategies of antiviral and mAbs, alone or in combination, with extended and unconventional durations of therapies, have been proposed for hospitalized patients with prolonged SARS-CoV-2 infection, but these need more robust data to support the evidence of their efficacy.

This collection aims to approach the clinical, virological, immunological, and epidemiological aspects of administering treatment against COVID-19.

Without available data from randomized clinical trials, investigations about the impact of the different authorized treatments could address a more tailored and timed treatment approach. Exploring new outcomes of treatment evaluation and finding new surrogate markers of efficacy could also be useful for the future design of new drug studies.

Finally, the relationship between in vitro and in vivo efficacy of drugs needs to be explored to clarify better the mechanisms of actions of the drugs used, as well as the immunological mechanisms underlying the eradication of SARS-CoV-2 in certain kinds of patients need to be explored.

We encourage the submission of randomized trials as well as observational human cohort studies, retrospective and/or prospective, and case series or case reports that delve into specific, unresolved aspects. Review articles will also be considered.

We expect submissions based on (but not limited to):

• Human cohorts treated for COVID-19, which could provide real world evidence on the efficacy of treatments
• Treatment of special populations (e.g., Aged, unvaccinated, hematological, transplant recipient, immunosuppressed)
• Unconventional treatment schedules (as combination therapies)
• Predictors of clinical and virological failure
• Viral dynamic and evolution after treatment
• The emergence of mutations and resistance to drugs
• Impact of treatments on the immune response to infection
• Impact of treatment on transmissibility
• Management of drug-drug interaction
• Management of adverse effect

Keywords: COVID-19, SARS-CoV-2, Antiviral, monoclonal antibodies, therapy, resistance, sublineages, immune response, neutralization, transmission

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

    In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.

Impact

  • 18kTopic views
  • 12kArticle views
  • 5,925Article downloads
View impact